Comparison of preoperative prostate specific antigen density and prostate specific antigen for predicting recurrence after radical prostatectomy: Results from the search data base

被引:40
作者
Freedland, SJ
Kane, CJ [1 ]
Presti, JC
Terris, MK
Amling, CL
Dorey, F
Aronson, WJ
机构
[1] Univ Calif Los Angeles, Sch Med, Dept Urol, Los Angeles, CA 90024 USA
[2] Univ Calif Los Angeles, Sch Med, Dept Biostat, Los Angeles, CA USA
[3] Vet Adm Greater Los Angeles Healthcare Syst, Dept Surg, Los Angeles, CA USA
[4] Univ Calif San Francisco, Dept Urol, Sch Med, San Francisco, CA 94143 USA
[5] Stanford Univ, Sch Med, Dept Urol, Stanford, CA 94305 USA
[6] San Diego Naval Hosp, Dept Urol, San Diego, CA USA
[7] Med Coll Georgia, Div Urol, Augusta, GA 30912 USA
关键词
prostate; prostatic neoplasms; prostatectomy; prostate-specific antigen; tumor markers; biological;
D O I
10.1097/01.ju.0000051400.85694.bb
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
Purpose: Prostate specific antigen (PSA) density based on the surgical weight of the radical prostatectomy specimen has previously been shown to be an independent predictor of biochemical recurrence after radical prostatectomy. We determined whether preoperative PSA density calculated using transrectal ultrasound prostate volume was a better predictor of advanced pathological findings or biochemical recurrence after radical prostatectomy relative to PSA. Materials and Methods: We examined 552 men from the newly established Shared Equal Access Regional Cancer Hospital data base of men treated with radical prostatectomy at equal access medical centers to determine whether preoperative PSA density was a significant predictor of an adverse pathological condition or PSA recurrence after radical prostatectomy. Models using PSA density were compared with models using PSA to determine whether PSA density improved risk stratification relative to PSA. PSA density was examined as a continuous and a categorical variable using cutoffs to separate patients into groups at different risks for PSA failure. Results: PSA density and PSA were significant predictors of adverse pathological findings on univariate analysis. Using PSA density in the multivariate model resulted in slightly better but statistically insignificant improvement in prediction of positive surgical margins (p = 0.134) and extracapsular extension (p = 0.771) relative to using PSA in the model. Neither PSA nor PSA density were significant independent predictors of seminal vesicle invasion. Area under the ROC curves for predicting biochemical recurrence for PSA and PSA density were not significantly different (0.589 and 0.58, respectively, p = 0.691). On separate multivariate analyses PSA density and PSA were significant independent predictors of biochemical failure. The multivariate model using PSA density provided only slight improvement in risk assessment relative to the model using PSA (index C = 0.589 and 0.581, respectively). To determine whether using PSA density as a categorical variable would result in improved prognostication we evaluated PSA density to determine the cutoff points that would provide the greatest risk stratification. PSA density cutoffs of less than 0.4, 0.4 to 1 and greater than 1 ng./ml./cc separated patients into 3 distinct groups at increasing risk for biochemical failure (p < 0.001). While these cutoffs provided better risk stratification than when PSA density was examined as a continuous variable (index C = 0.684 versus 0.58), they provided only marginal improvement relative to the standard PSA cutoffs of less than 10, 10 to 20 and greater than 20 ng./ml. (index C = 0.676). Conclusions: The use of preoperative PSA density relative to PSA provided only slight improvement for predicting adverse pathological findings and biochemical recurrence after radical prostatectomy. The minimal and statistically insignificant improvement in preoperative risk assessment provided by PSA density does not justify the time and effort necessary to calculate this value.
引用
收藏
页码:969 / 973
页数:5
相关论文
共 16 条
  • [1] Extensive repeat transrectal ultrasound guided prostate biopsy in patients with previous benign sextant biopsies
    Borboroglu, PG
    Comer, SW
    Riffenburgh, RH
    Amling, CL
    [J]. JOURNAL OF UROLOGY, 2000, 163 (01) : 158 - 162
  • [2] Systematic sextant biopsies in the prediction of extracapsular extension at radical prostatectomy
    Borirakchanyavat, S
    Bhargava, V
    Shinohara, K
    Toke, A
    Carroll, PR
    Presti, JC
    [J]. UROLOGY, 1997, 50 (03) : 373 - 378
  • [3] Comparison of percent free PSA, PSA density, and age-specific PSA cutoffs for prostate cancer detection and staging
    Catalona, WJ
    Southwick, PC
    Slawin, KM
    Partin, AW
    Brawer, MK
    Flanigan, RC
    Patel, A
    Richie, JP
    Walsh, PC
    Scardino, PT
    Lange, PH
    Gasior, GH
    Loveland, KG
    Bray, KR
    [J]. UROLOGY, 2000, 56 (02) : 255 - 260
  • [4] Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer
    D'Amico, AV
    Whittington, R
    Malkowicz, SB
    Schultz, D
    Blank, K
    Broderick, GA
    Tomaszewski, JE
    Renshaw, AA
    Kaplan, I
    Beard, CJ
    Wein, A
    [J]. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1998, 280 (11): : 969 - 974
  • [5] Clinical utility of the percentage of positive prostate biopsies in defining biochemical outcome after radical prostatectomy for patients with clinically localized prostate cancer
    D'Amico, AV
    Whittington, R
    Malkowicz, SB
    Schultz, D
    Fondurulia, J
    Chen, MH
    Tomaszewski, JE
    Renshaw, AA
    Wein, A
    Richie, JP
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2000, 18 (06) : 1164 - 1172
  • [6] Race is not an independent predictor of biochemical recurrence after radical prostatectomy in an equal access medical center
    Freedland, SJ
    Jalkut, M
    Dorey, F
    Sutter, ME
    Aronson, WJ
    [J]. UROLOGY, 2000, 56 (01) : 87 - 91
  • [7] Improved risk stratification for biochemical recurrence after radical prostatectomy using a novel risk group system based on prostate specific antigen density and biopsy Gleason score
    Freedland, SJ
    Wieder, JA
    Jack, GS
    Dorey, F
    deKernion, JB
    Aronson, WJ
    [J]. JOURNAL OF UROLOGY, 2002, 168 (01) : 110 - 115
  • [8] Race as an outcome predictor after radical prostatectomy: Results from the shared equal access regional cancer hospital (search) database
    Freedland, SJ
    Amling, CL
    Dorey, F
    Kane, CJ
    Presti, JC
    Terris, MK
    Aronson, WJ
    [J]. UROLOGY, 2002, 60 (04) : 670 - 674
  • [9] Percent prostate needle biopsy tissue with cancer is more predictive of biochemical failure or adverse pathology after radical prostatectomy than prostate specific antigen or Gleason score
    Freedland, SJ
    Csathy, GS
    Dorey, F
    Aronson, WJ
    [J]. JOURNAL OF UROLOGY, 2002, 167 (02) : 516 - 520
  • [10] Horninger W, 1999, PROSTATE, V40, P56